🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Umeclidinium matching placebo

Found 20 matching trials

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

PHASE2

This study will evaluate the efficacy and safety data of AZD8871 in patient...

Status

Completed

Location

Research Site

Start Date

2018-10-10

Trial ID

NCT03645434

Treatments Being Tested

AZD8871 Anoro® Ellipta®

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

PHASE3

After screening, subjects will enter a 4 week open-label run-in period with...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10

Trial ID

NCT02119286

Treatments Being Tested

FF VI UMEC Placebo

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This is a multicenter, randomized, double-blind, double-dummy, parallel gro...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-04-04

Trial ID

NCT01822899

Treatments Being Tested

Umeclidinium bromide/Vilanterol Placebo ACCUHALER/DISKUS Fluticasone propionate/Salmeterol Placebo NDPI

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The primary purpose of this study is to assess the equivalence of closed tr...

Status

Withdrawn

Location

GSK Investigational Site

Start Date

2016-06

Trial ID

NCT02731846

Treatments Being Tested

Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg Fluticasone furoate 100 mcg + Vilanterol 25 mcg Umeclidinium 62.5 mcg Placebo ELLIPTA inhaler Albuterol/Salbutamol

Aura Adolescent PK Study GSK2829332

PHASE2

This is a randomized, double-blind, placebo-controlled, repeat dose, 2-peri...

Status

Withdrawn

Location

Multiple Locations

Start Date

2012-09

Trial ID

NCT01653483

Treatments Being Tested

GSK573719 GSK573719matched-placebo

A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

This is a multicenter, randomized, double-blind, parallel-group study to ev...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-30

Trial ID

NCT02257372

Treatments Being Tested

UMEC DPI Placebo DPI ICS/LABA medication Albuterol/salbutamol Metered Dose Inhaler (MDI)

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

PHASE3

The purpose of this study is to demonstrate that the efficacy of the combin...

Status

Completed

Location

Novartis Investigative Site

Start Date

2015-07-27

Trial ID

NCT02487498

Treatments Being Tested

QVA149 Umeclidinium/vilanterol Placebo (umeclidinium/vilanterol )Placebo (QVA149)

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

PHASE1

CHF6366 is a novel bifunctional compound displaying both muscarinic recepto...

Status

Completed

Location

Medicines Evaluation Unit

Start Date

2017-12-28

Trial ID

NCT03378648

Treatments Being Tested

CHF6366 Placebo CHF6366 umeclidinium bromide and vilanterol trifenatate

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

PHASE2

This is a multi-national, randomized, double-blind, 3-period crossover, inc...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-05

Trial ID

NCT01641692

Treatments Being Tested

GSK573719 Active treatment or Placebo GSK573719 (Sub-group cohort)Salbutamol/Albuterol

Previous Next